Fiorina et al. showed the efficacy of Abatacept (CTLA4-Ig) in B7-1 inhibition on podocytes as a potential therapeutic strategy for the treatment of proteinuria in DKD in patients with podocyte B7-1–positive FSGS [41]. This evidence concerns the gene CD80 and diabetic kidney disease.